Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Niagen Bioscience (NAGE) over the last 13 years, with Q3 2025 value amounting to -$938000.0.

  • Niagen Bioscience's Change in Account Payables rose 2196.34% to -$938000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 38226.58%. This contributed to the annual value of -$1.1 million for FY2024, which is 29294.76% down from last year.
  • Niagen Bioscience's Change in Account Payables amounted to -$938000.0 in Q3 2025, which was up 2196.34% from $3.0 million recorded in Q2 2025.
  • Niagen Bioscience's Change in Account Payables' 5-year high stood at $3.0 million during Q2 2025, with a 5-year trough of -$2.3 million in Q1 2024.
  • Its 5-year average for Change in Account Payables is $207157.9, with a median of $206000.0 in 2024.
  • In the last 5 years, Niagen Bioscience's Change in Account Payables crashed by 22925.66% in 2022 and then surged by 137961.17% in 2025.
  • Over the past 5 years, Niagen Bioscience's Change in Account Payables (Quarter) stood at -$381000.0 in 2021, then surged by 246.98% to $560000.0 in 2022, then soared by 84.64% to $1.0 million in 2023, then surged by 118.76% to $2.3 million in 2024, then plummeted by 141.47% to -$938000.0 in 2025.
  • Its Change in Account Payables was -$938000.0 in Q3 2025, compared to $3.0 million in Q2 2025 and $2.1 million in Q1 2025.